# Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study

> Data are scarce regarding both the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing immune cell therapy; thus, we prospectively evaluated these two domains in patients receiving this vaccine after allogeneic hematopoietic cell transplantation (HCT; n = 66) or af...

## Metadata
- Authors: Ron Ram, David Hagin, Nino Kikozashvilli, Tal Freund, Odelia Amit, Yael Bar‐On, Ofrat Beyar‐Katz, Gabi Shefer, M. Morales, Chen Karni, Ronit Gold, Sigi Kay, Chen Glait‐Santar, Rinat Eshel, Chava Perry, Irit Avivi, Arie Apel, Noam Benyamini, David Shasha, Ronen Ben‐Ami
- Journal: Transplantation and Cellular Therapy
- Published: 2021-06-30
- DOI: https://doi.org/10.1016/j.jtct.2021.06.024
- Citations: 162
- Source: OpenAlex
- Access: Open Access

## Technology Hub
- Hub: mRNA Therapies
- Discipline: Medicine / Biotechnology
- Hub URL: https://science-database.com/technology/mrna-therapies
- Hub llms.txt: https://science-database.com/technology/mrna-therapies/llms.txt

## Abstract
Data are scarce regarding both the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing immune cell therapy; thus, we prospectively evaluated these two domains in patients receiving this vaccine after allogeneic hematopoietic cell transplantation (HCT; n = 66) or after CD19-based chimeric antigen receptor T cell (CART) therapy (n = 14). Overall, the vaccine was well tolerated, with mild non-hematologic vaccine-reported adverse events in a minority of the patients. Twelve percent of the patients after the first dose and 10% of the patients after the second dose developed cytopenia, and there were three cases of graft-versus-host disease exacerbation after each dose. A single case of impending graft rejection was summarized as possibly related. Evaluation of immunogenicity showed that 57% of patients after CART infusion and 75% patients after allogeneic HCT had evidence of humoral and/or cellular response to the vaccine. The Cox regression model indicated that longer time from infusion of cells, female sex, and higher CD19<sup>+</sup> cells were associated with a positive humoral response, whereas a higher CD4<sup>+</sup>/CD8<sup>+</sup> ratio was correlated with a positive cellular response, as confirmed by the ELISpot test. We conclude that the BNT162b2 mRNA COVID-19 vaccine has impressive immunogenicity in patients after allogeneic HCT or CART. Adverse events were mostly mild and transient, but some significant hematologic events were observed; hence, patients should be closely monitored.

## Links
- DOI: https://doi.org/10.1016/j.jtct.2021.06.024
- OpenAlex: https://openalex.org/W3175432865
- PDF: https://doi.org/10.1016/j.jtct.2021.06.024
- JSON API: https://science-database.com/api/v1/technology/mrna-therapies

---
Generated by science-database.com — The Knowledge Interface
Paper ID: oa-W3175432865 | Hub: mrna-therapies